Las Vegas, NV -- (SBWIRE) -- 10/17/2013 -- Himax Technologies (NASDAQ:HIMX), , Enduro Royalty Trust (NYSE:NDRO) , Alnylam Pharmaceuticals (NASDAQ: ALNY) , Zoltek Companies Inc.(NASDAQ:ZOLT)
PennyStockParlay.com Our process for picking penny stocks is not only unconventional, but untapped, undiscovered, and also exclusive. To keep our picks consistent with how only the "Best Penny Stocks" perform in the penny stock market, we have to keep our penny stock picks producing large and consistent gains.Have a look at today’s active stocks:
Himax Technologies (NASDAQ:HIMX), Inc. operates as an IC design house with LCD manufacturing capability. The Company focuses on display IC products for display device and offers LCD technical consulting to customers to provide them with value-added technical support and integrated solutions.
Himax Technologies changed hands lower -4.24% on a volume of 9.64 million, lower than its standard daily volume of 12 million shares.
Why Should Investors Buy HIMX After the Recent Fall? Just Go Here and Find Out
Enduro Royalty Trust (the Trust) is a statutory trust. On May 13, 2011, the Trust was formed by Enduro Resource Partners LLC (Enduro Sponsor) to own a net profits interest representing the right to receive 80% of the net profits from the sale of oil and natural gas production from certain properties in the states of Texas, Louisiana and New Mexico.
Enduro Royalty Trust (NYSE:NDRO) shares shed 13% to $12.05. Over the past 3months, the stock has declined -24% and past five days performance showed bearish change of 20.41%
Will NDRO Get Buyers Even After The Recent Rally? Find Out Here
Harwood Feffer LLP (www.hfesq.com) is looking into possible claims against the board of directors of Zoltek Companies Inc. ("Zoltek" or the "Company") (NASDAQ:ZOLT) concerning the proposed acquisition of the Company by Toray Industries Inc. ("Toray").
Can Investors Bet on ZOLT after this News update? Find out in this Research Report
Alnylam Pharmaceuticals (NASDAQ: ALNY) performed a strong action for investors this week, with shares rallying almost 12% over the last five days.
Is ALNY a Solid Investment at These Levels? Read This Report For Details
The firm makes therapies founded on RNA interference, and the firm declared in the start of this week that its treatment for TTR-mediated amyloidosis (ATTR), ALN-TTRsc, was accomplished in a phase 1 trial. The drug lowered specific protein levels by 94% in the experiment and was well tolerated in the patient group, as per reported by the firm.
Penny stocks are stocks that can be traded in the stock market at a very cheap price. The investor who decides to buy penny stocks should have a substantial intellect of the market and should be bequeathing to possibly suffer a loss in money. The phrase penny stock is usually used for stock dealing that does not imply the greater and popularly known exchanges.
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list. Never invest into a stock discussed on this web site or the PennyStockParlay.comnewsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
PennyStockParlay.com and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your investment manager before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies in the profiled on the PennyStockParlay.com web site and/or newsletter involve a high degree of risk and volatility, and all investors should know that they may lose a portion or all of their investment if they decide to purchase any stock.
Read Full Disclaimer at: http://pennystockparlay.com/disclaimer.html
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)